Aptevo Therapeutics: Inside a Top-Tier Oncology Pipeline with COO Jeff Lamothe

Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies through its proprietary bispecific antibody platforms, ADAPTIR® and ADAPTIR-FLEX®. The company is advancing a diverse pipeline that includes both clinical and preclinical candidates designed to harness the immune system to target hematologic and solid tumors with greater precision and safety. With a focus on innovation, Aptevo is leveraging modular antibody engineering to address areas of high unmet medical need and capture opportunities across multi-billion-dollar oncology markets.Aptevo Therapeutics is a client of RedChip. Visit APVOinfo.com to learn more.